Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBsolvMIR in Islet Transplantation
NCT03867851Phase 2Terminated
- Sponsor
- TikoMed
- Start
- Feb 2021
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of ilb in type 1 diabetes mellitus (T1D) (2 arms), sponsored by TikoMed. Primary endpoints: Bleeding events at 44 days and Other AEs/SAEs after islet transplantation at 44 days. Started Feb 2021; status: terminated.
02
Drugs
ilb
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03867851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03867851.